Loading...

PureTech Health

LSE:PRTC
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PRTC
LSE
£661M
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

PureTech Health plc, a biopharmaceutical company, focuses on developing medicines for dysfunctions of the Brain-Immune-Gut axis. The last earnings update was 60 days ago. More info.


Add to Portfolio Compare Print
  • PureTech Health has significant price volatility in the past 3 months.
PRTC Share Price and Events
7 Day Returns
0%
LSE:PRTC
-1%
GB Life Sciences
0.3%
GB Market
1 Year Returns
48.6%
LSE:PRTC
10.2%
GB Life Sciences
-3.8%
GB Market
PRTC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
PureTech Health (PRTC) 0% 17% 41.8% 48.6% 65.4% -
GB Life Sciences -1% 3% 15.4% 10.2% 36.8% 52.3%
GB Market 0.3% 1.8% 2.4% -3.8% 18.5% 4.5%
1 Year Return vs Industry and Market
  • PRTC outperformed the Life Sciences industry which returned 10.2% over the past year.
  • PRTC outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -3.8% over the past year.
Price Volatility
PRTC
Industry
5yr Volatility vs Market

Value

 Is PureTech Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for PureTech Health. This is due to cash flow or dividend data being unavailable. The share price is £2.34.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for PureTech Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are PureTech Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
LSE:PRTC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.16
LSE:PRTC Share Price ** LSE (2019-06-21) in GBP £2.34
LSE:PRTC Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.27 $2.97
Europe Life Sciences Industry PE Ratio Median Figure of 16 Publicly-Listed Life Sciences Companies 38.16x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 787 Publicly-Listed Companies 16.39x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of PureTech Health.

LSE:PRTC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= LSE:PRTC Share Price ÷ EPS (both in USD)

= 2.97 ÷ -0.16

-18.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PureTech Health is loss making, we can't compare its value to the Europe Life Sciences industry average.
  • PureTech Health is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does PureTech Health's expected growth come at a high price?
Raw Data
LSE:PRTC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -18.64x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-13.4%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 12 Publicly-Listed Life Sciences Companies 2.69x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 573 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for PureTech Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on PureTech Health's assets?
Raw Data
LSE:PRTC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.98
LSE:PRTC Share Price * LSE (2019-06-21) in GBP £2.34
LSE:PRTC Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.27 $2.97
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry PB Ratio Median Figure of 13 Publicly-Listed Life Sciences Companies 2.03x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,371 Publicly-Listed Companies 1.49x
LSE:PRTC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= LSE:PRTC Share Price ÷ Book Value per Share (both in USD)

= 2.97 ÷ 0.98

3.05x

* Primary Listing of PureTech Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PureTech Health is overvalued based on assets compared to the GB Life Sciences industry average.
X
Value checks
We assess PureTech Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. PureTech Health has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is PureTech Health expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-13.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is PureTech Health expected to grow at an attractive rate?
  • Unable to compare PureTech Health's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare PureTech Health's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as it is expected to be loss making during the next 1-3 years.
  • PureTech Health's revenues are expected to decrease over the next 1-3 years, this is below the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
LSE:PRTC Future Growth Rates Data Sources
Data Point Source Value (per year)
LSE:PRTC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -13.4%
LSE:PRTC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts -43.4%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 23.5%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average -1.8%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 10.9%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
LSE:PRTC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
LSE:PRTC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 0 -99 -79 1
2022-12-31 1 -110 -70 1
2021-12-31 12 -100 -59 2
2020-12-31 17 -96 -50 2
2019-12-31 41 -28 -42 1
LSE:PRTC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 21 -73 -44
2018-09-30 14 -81 9
2018-06-30 7 -88 65
2018-03-31 5 -88 48
2017-12-31 3 -89 26
2017-09-30 4 -81 -17
2017-06-30 5 -74 -61
2017-03-31 5 -66 -55
2016-12-31 4 -58 -49
2016-09-30 3 -57 -54
2016-06-30 1 -55 -59
2016-03-31 6 -42 -49

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • PureTech Health is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • PureTech Health's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
LSE:PRTC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from PureTech Health Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

LSE:PRTC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.30 -0.30 -0.30 1.00
2022-12-31 -0.20 -0.20 -0.20 1.00
2021-12-31 -0.20 -0.20 -0.20 1.00
2020-12-31 -0.20 -0.20 -0.20 1.00
2019-12-31 -0.10 -0.10 -0.10 1.00
LSE:PRTC Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.16
2018-09-30 0.03
2018-06-30 0.26
2018-03-31 0.20
2017-12-31 0.11
2017-09-30 -0.07
2017-06-30 -0.26
2017-03-31 -0.24
2016-12-31 -0.21
2016-09-30 -0.24
2016-06-30 -0.26
2016-03-31 -0.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if PureTech Health will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess PureTech Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
PureTech Health has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has PureTech Health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare PureTech Health's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • PureTech Health does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare PureTech Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare PureTech Health's 1-year growth to the Europe Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
PureTech Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from PureTech Health Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

LSE:PRTC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 20.75 -43.65 47.37
2018-09-30 13.80 8.51 47.71
2018-06-30 6.85 65.06 48.05
2018-03-31 4.69 47.97 47.17
2017-12-31 2.54 26.47 46.28
2017-09-30 3.69 -17.25 43.12 -7.66
2017-06-30 4.85 -60.98 39.96 -15.31
2017-03-31 4.64 -54.89 38.56 -7.66
2016-12-31 4.43 -48.79 37.16
2016-09-30 2.76 -54.14 38.61 13.80
2016-06-30 1.08 -59.49 40.07 27.61
2016-03-31 6.46 -49.44 38.27 23.30
2015-12-31 11.83 -39.39 36.47 19.00
2015-09-30 11.95 -37.27 31.32 14.52
2015-06-30 12.07 -35.15 26.16 10.04
2015-03-31 7.15 -38.40 20.28 7.66
2014-12-31 2.22 -41.64 14.40 5.27
2013-12-31 8.50 -4.73 7.17 4.42
2012-12-31 8.02 -10.12 8.46 5.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if PureTech Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if PureTech Health has efficiently used its assets last year compared to the Europe Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if PureTech Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess PureTech Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
PureTech Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is PureTech Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up PureTech Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • PureTech Health's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • PureTech Health's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of PureTech Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 21.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from PureTech Health Company Filings, last reported 5 months ago.

LSE:PRTC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 166.97 12.01 250.88
2018-09-30 166.97 12.01 250.88
2018-06-30 217.06 12.44 200.41
2018-03-31 217.06 12.44 200.41
2017-12-31 59.60 7.46 188.75
2017-09-30 59.60 7.46 188.75
2017-06-30 32.66 7.32 248.42
2017-03-31 32.66 7.32 248.42
2016-12-31 92.41 6.95 281.47
2016-09-30 92.41 6.95 281.47
2016-06-30 125.80 5.42 263.14
2016-03-31 125.80 5.42 263.14
2015-12-31 164.05 4.96 313.71
2015-09-30 164.05 4.96 313.71
2015-06-30 183.73 3.33 291.61
2015-03-31 183.73 3.33 291.61
2014-12-31 -23.31 6.95 62.66
2013-12-31 -8.03 4.26 8.88
2012-12-31 -3.35 1.46 11.91
  • PureTech Health's level of debt (7.2%) compared to net worth is satisfactory (less than 40%).
  • PureTech Health had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • PureTech Health has sufficient cash runway for more than 3 years based on current free cash flow.
  • PureTech Health has sufficient cash runway for 2.7 years if free cash flow continues to grow at historical rates of 23.2% each year.
X
Financial health checks
We assess PureTech Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. PureTech Health has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is PureTech Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from PureTech Health dividends. Estimated to be 0% next year.
If you bought £2,000 of PureTech Health shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate PureTech Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate PureTech Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
LSE:PRTC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 0.8%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 706 Stocks 4.3%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

LSE:PRTC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as PureTech Health has not reported any payouts.
  • Unable to verify if PureTech Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of PureTech Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as PureTech Health has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of PureTech Health's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess PureTech Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can PureTech Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. PureTech Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of PureTech Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Daphne Zohar
COMPENSATION $821,898
AGE 47
CEO Bio

Ms. Daphne Zohar is the Founder of PureTech Health plc and serves as its Chief Executive Officer, Managing Partner and Executive Director. Ms. Zohar co-founded Tal Medical, Inc. in 2010. She was a Director of resTORbio, Inc. since December 2017 until November 5, 2018. She is the Founder of Peerin and serves as its Chief Executive Officer. Ms. Zohar serves as Founding Chief Executive Officer of Mandara Sciences, LLC. She served as Acting Chief Executive Officer of Vedanta Biosciences, Inc. Ms. Zohar is the Founder of Akili Interactive Labs, Inc. and served as its Chief Executive Officer. She co-founded Follica, Inc. in 2005 and served as its Founding Chief Executive Officer until May 13, 2009. She is the Founder of Satori Pharmaceuticals Incorporated and served as its Interim Chief Executive Officer until January 8, 2009. She served as the Chief Executive Officer at Solace Pharmaceuticals, Inc. until May 14, 2007. She was Founder and Managing Partner of Karuna Pharmaceuticals Inc. and is Director. Ms. Zohar’s career has focused on early stage venture creation and prior to her focus on life sciences, she was the Founder of several companies in diverse industries including EQ Inc., Zeta Ltd., which achieved leadership in the Israeli market and was subsequently sold to one of Israel's largest food companies and Kicks Inc. She serves as a Director of Tal Medical, Inc. Ms. Zohar serves as a Director of Follica, Inc., Enlight Biosciences LLC and PureTech Ventures. She sits on the Boards of Akili Interactive Labs Inc., The Sync Project, Vedanta Bioscience, Mandara Sciences, Neovasc Medical and Satori Pharmaceuticals Incorporated and is a Member of the Board of Associates of the Whitehead Institute. She also sits on the Technology Development Fund Advisory Board at Children's Hospital Boston and is an Editorial Advisor to Xconomy. She served as a Director of Karuna Pharmaceuticals Inc., Endra, Inc. (ENDRA Life Sciences Inc.) and Solace Pharmaceuticals, Inc. She is also a sucessful entrepreneur. She is a Member of the Distinguished Faculty of the Biotechnology and the Ethical Imagination Global Summit organised by the Emory University Center for Ethics. She was recognized by Fierce Biotech as one of the “Top 10 Women in Biotech,” BioWorld as one of 28 leaders predicted to be the “movers and shakers” of the biotechnology industry over the next 20 years and by the Boston Globe as one of the “Top 15 Innovators. Ms. Zohar has also co-founded and currently sits on the board of directors of a number of private life science companies, as well as on the board of PureTech Health plc, which is FTSE indexed and listed on the main market of the London Stock Exchange. Ms. Zohar has been recognized as a top leader and innovator in biotechnology by a number of sources such as Scientific American. In 2003, she was named one of the world's top young innovators by MIT's Technology Review Magazine and one of the top ‘40 under 40’ by the Boston Business Journal. Ms. Zohar has been an entrepreneur since an early age and received her B.A. in entrepreneurship and new venture creation from Northeastern University. Ms. Zohar attended the exclusive Tefen Entrepreneurial College in Israel.

CEO Compensation
  • Daphne's compensation has increased whilst company is loss making.
  • Daphne's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the PureTech Health management team in years:

2.7
Average Tenure
58.5
Average Age
  • The tenure for the PureTech Health management team is about average.
Management Team

Daphne Zohar

TITLE
Founder
COMPENSATION
$822K
AGE
47

Ben Shapiro

TITLE
Co-Founder & Non-Executive Director
COMPENSATION
$125K
AGE
78

Bob Langer

TITLE
Co-Founder
COMPENSATION
$110K
AGE
69

Steve Muniz

TITLE
COO, Executive VP of Legal & Operations
COMPENSATION
$559K
AGE
48
TENURE
11.6 yrs

Bharatt Chowrira

TITLE
President and Chief of Business & Strategy
AGE
53
TENURE
2.3 yrs

David Elmaleh

TITLE
Co-Founder & Senior Advisor
AGE
70

Joep Muijrers

TITLE
Chief Financial Officer
TENURE
1.2 yrs

Joe Bolen

TITLE
Chief Scientific Officer
AGE
64
TENURE
2.7 yrs

Allison Talbot

TITLE
Vice President of Communications & Investor Relations

Eric Elenko

TITLE
Chief Innovation Officer
AGE
45
TENURE
2.7 yrs
Board of Directors Tenure

Average tenure and age of the PureTech Health board of directors in years:

4.4
Average Tenure
68
Average Age
  • The tenure for the PureTech Health board of directors is about average.
Board of Directors

Joi Ito

TITLE
Chairman of the Board of Directors
COMPENSATION
$150K
AGE
52

Daphne Zohar

TITLE
Founder
COMPENSATION
$822K
AGE
47

Ben Shapiro

TITLE
Co-Founder & Non-Executive Director
COMPENSATION
$125K
AGE
78

Bob Langer

TITLE
Co-Founder
COMPENSATION
$110K
AGE
69

Steve Muniz

TITLE
COO, Executive VP of Legal & Operations
COMPENSATION
$559K
AGE
48

David Elmaleh

TITLE
Co-Founder & Senior Advisor
AGE
70

John LaMattina

TITLE
Independent Non-Executive Director
COMPENSATION
$105K
AGE
68
TENURE
10.4 yrs

H. Horvitz

TITLE
Board Advisor & Chair of Scientific Advisory Board
TENURE
3.6 yrs

Chris Viehbacher

TITLE
Independent Non-Executive Director
COMPENSATION
$95K
AGE
57
TENURE
4.4 yrs

Marjorie Scardino

TITLE
Senior Independent Director
COMPENSATION
$90K
AGE
71
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
X
Management checks
We assess PureTech Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. PureTech Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Kind Of Shareholders Own PureTech Health plc (LON:PRTC)?

Every investor in PureTech Health plc (LON:PRTC) should be aware of the most powerful shareholder groups. … PureTech Health is a smaller company with a market capitalization of UK£460m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company

Simply Wall St -

Update: PureTech Health (LON:PRTC) Stock Gained 11% In The Last Three Years

Unfortunately for shareholders, while the PureTech Health plc (LON:PRTC) share price is up 11% in the last three years, that falls short of the market return. … Unfortunately, the share price has fallen 1.5% over twelve months. … One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

Simply Wall St -

The PureTech Health plc (LON:PRTC) Ownership Structure Could Be Important

The big shareholder groups in PureTech Health plc (LON:PRTC) have power over the company. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … With a market capitalization of UK£456.9m, PureTech Health is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Does PureTech Health plc (LON:PRTC) Fall With The Market?

For PureTech Health plc’s (LON:PRTC) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. … The second risk is market-wide, which arises from investing in the stock market. … A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one.

Simply Wall St -

Is PureTech Health plc's (LON:PRTC) Balance Sheet A Threat To Its Future?

While small-cap stocks, such as PureTech Health plc (LON:PRTC) with its market cap of US$395.40m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

PureTech Health plc (LON:PRTC): Earnings Expected To Remain Subdued

The latest earnings update PureTech Health plc (LON:PRTC) released in December 2017 … finally turned profitable … negative earnings

Simply Wall St -

What Should We Expect From PureTech Health plc's (LON:PRTC) Earnings In The Next Couple Of Years?

The most recent earnings release PureTech Health plc's (LSE:PRTC) announced in December 2017 confirmed that the business finally turned profitable after delivering negative earnings on average over the last few years. … Below is my commentary, albeit very simple and high-level, on how market analysts predict PureTech Health's earnings growth outlook over the next few years and whether the future looks brighter. … See our latest analysis for PureTech Health Market analysts' consensus outlook for the coming year seems pessimistic, with earnings turning into a loss in 2019.

Simply Wall St -

Does PureTech Health plc's (LON:PRTC) PE Ratio Warrant A Buy?

Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for PRTC Price per share = $2.02 Earnings per share = $0.131 ∴ Price-Earnings Ratio = $2.02 ÷ $0.131 = 15.4x On its own, the P/E ratio doesn’t tell you much; however, it becomes extremely useful when you compare it with other similar companies. … For example, if you accidentally compared higher growth firms with PRTC, then PRTC’s P/E would naturally be lower since investors would reward its peers’ higher growth with a higher price. … Alternatively, if you inadvertently compared less risky firms with PRTC, PRTC’s P/E would again be lower since investors would reward its peers’ lower risk with a higher price as well.

Simply Wall St -

Should Your Next Investment In The Healthcare Industry Be In PureTech Health plc (LON:PRTC)?

View our latest analysis for PureTech Health What’s the catalyst for PureTech Health's sector growth? … PureTech Health lags the pack with its sustained negative earnings over the past couple of years. … Next Steps: PureTech Health's uncertain outlook is concerning for investors, with the prospect of negative earnings persisting into the future.

Simply Wall St -

What You Must Know About PureTech Health plc's (LON:PRTC) Major Investors

See our latest analysis for PureTech Health LSE:PRTC Ownership_summary Jan 13th 18 Institutional Ownership In PRTC's case, institutional ownership stands at 57.27%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … Insider Ownership Another important group of shareholders are company insiders. … Private Company Ownership Another important group of owners for potential investors in PRTC are private companies that hold a stake of 5.35% in PRTC.

Simply Wall St -

Company Info

Description

PureTech Health plc, a biopharmaceutical company, focuses on developing medicines for dysfunctions of the Brain-Immune-Gut axis. The company is developing a digital medicine platform for the treatment and assessment of cognitive dysfunction across various neurological and psychiatric indications; therapies to treat a range of acute and chronic inflammatory disorders, and cancer; microbiome-derived immune modulators for immune and infectious diseases; oral delivery approach of biologics, vaccines, and other drugs; platform to address androgenetic alopecia and aesthetic-related indications; mechanotherapeutics to treat obesity, and other chronic diseases related to the gastrointestinal pathway; muscarinic receptor agonist program for the treatment of psychosis and cognition, including schizophrenia and Alzheimer’s disease; monoclonal antibody-based therapeutics to treat pancreatic cancer and other solid tumors; and voice-based technology platform for monitoring and diagnosing psychological and physical medical conditions, such as depression, Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease, as well as cardiovascular and respiratory diseases. It is also developing a milk exosome-based technology designed to enable the oral administration of nucleic acids, peptides, and small molecules; and a lipid transport mechanism to substantially enhance the transport of compounds into the lymphatic system from an oral route. In addition, the company offers a suite of medical device products for patients, caregivers, and doctors. PureTech Health plc has a collaboration with Boehringer Ingelheim to advance immuno-oncology product candidates, as well as with Roche to advance its milk-derived exosome technology; and research and development partnerships with Bristol-Myers Squibb, University of Nebraska, University of Virginia, and University of California, San Francisco. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Details
Name: PureTech Health plc
PRTC
Exchange: LSE
Founded: 2015
£661,035,648
282,493,867
Website: http://www.puretechhealth.com
Address: PureTech Health plc
6 Tide Street,
Boston,
Massachusetts, 02210,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
LSE PRTC Ordinary Shares London Stock Exchange GB GBP 19. Jun 2015
OTCPK PTCH.F Ordinary Shares Pink Sheets LLC US USD 19. Jun 2015
Number of employees
Current staff
Staff numbers
225
PureTech Health employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/23 22:27
End of day share price update: 2019/06/21 00:00
Last estimates confirmation: 2019/06/04
Last earnings filing: 2019/04/24
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.